GLP-1 receptor agonist treatment in women with polycystic ovary syndrome - a systematic review and meta-analysis
Abstract
Objective: To assess the effect of treatment with glucagon-like peptide-1 receptor agonists (GLP1-RAs) on weight-related, metabolic, and reproductive outcomes and health economics in women with polycystic ovary syndrome (PCOS).
Design: Systematic review and meta-analysis, Prospero CRD42024535096.
Methods: Cochrane Library, EMBASE, and Medline were searched on September 20, 2024 for studies including women with PCOS, comparing GLP1-RAs with no treatment, placebo, lifestyle intervention, combined oral contraceptives, antiandrogenic drugs, or metformin in randomized controlled trials (RCTs).
Results: A total of 9654 studies were identified, 365 read in full text and 11 RCTs were included. GLP1-RAs as an add-on showed a reduction in BMI compared to the control group, mean difference (95% CI), -1.38 (-2.39 to -0.38) kg/m2 (low certainty). For LDL cholesterol and triglycerides, no difference was noted between the groups (low certainty), whereas evidence was insufficient to draw conclusion regarding glucose, insulin, hirsutism, and menstrual regularity. No studies were identified assessing quality of life, mental health, or cost-effectiveness outcomes.
Conclusion: GLP-1-RAs are associated with modest short-term weight loss in women with PCOS and overweight or obesity. Evidence for benefits on metabolic, reproductive, or psychological outcomes remains uncertain due to low-quality data, and no studies have evaluated cost-effectiveness.
Trial registration: The protocol for the…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.